Abstract | BACKGROUND: METHODS: Patients with recurrent GBM were eligible. A novel sequential accrual trial design was used, where patients were sequentially accrued into separate treatment arms in phase I and phase II investigations to optimize recruitment efficiency. In phase I, a standard 3 + 3 format was used to identify dose-limiting toxicities (DLTs), determine maximum tolerated dose (MTD), and investigate pharmacokinetics. Phase II followed a 2-stage design with the primary endpoint being 6-month progression-free survival (PFS6). RESULTS: Sixteen patients were recruited for phase I, and the MTD was determined to be sorafenib 200 mg twice daily and erlotinib 100 mg once daily. DLTs include Grade 3 hypertension, Grade 3 elevated liver transaminases, and Grade 4 elevated lipase. While erlotinib did not affect sorafenib levels, sorafenib reduced erlotinib levels. In phase II, 3 of 19 stage 1 participants were progression free at 6 months. This did not meet the predetermined efficacy endpoint, and the trial was terminated. CONCLUSION: This study identified the MTD and DLTs for sorafenib and erlotinib combination therapy for recurrent GBMs; however, efficacy data did not meet the primary endpoint. This study also demonstrates the feasibility of a novel sequential accrual clinical trial design that optimizes patient recruitment for multiarm studies, which is particularly effective for multicenter clinical trials.
|
Authors | Huanwen Chen, John Kuhn, Kathleen R Lamborn, Lauren E Abrey, Lisa M DeAngelis, Frank Lieberman, H Ian Robins, Susan M Chang, W K Alfred Yung, Jan Drappatz, Minesh P Mehta, Victor A Levin, Kenneth Aldape, Janet E Dancey, John J Wright, Michael D Prados, Timothy F Cloughesy, Patrick Y Wen, Mark R Gilbert |
Journal | Neuro-oncology advances
(Neurooncol Adv)
2020 Jan-Dec
Vol. 2
Issue 1
Pg. vdaa124
ISSN: 2632-2498 [Electronic] England |
PMID | 33235994
(Publication Type: Journal Article)
|
Copyright | Published by Oxford University Press on behalf of the Society for Neuro-Oncology and the European Association of Neuro-Oncology 2020. |